This approach was tested in a murine model of prostate cancer, in which TRAMP mice were treated with the cellular vaccine GVAX (a cellular vaccine made from gene-modified tumor cells), anti-CTLA-4 blocking antibody, or the combination. Here, CTLA4 is linked to neoplasm.